MIMEDX to Host Fourth Quarter and Full Year 2022 Operating and Financial Results Conference Call on February 28
MiMedx Group (Nasdaq: MDXG) will report its fourth quarter and full year financial results for the period ending December 31, 2022 after the market closes on February 28, 2023. A conference call and webcast led by the senior management team will follow at 5:00 p.m. ET on the same day to discuss the results.
The company is a leader in placental biologics, focusing on various healthcare sectors like Advanced Wound Care and knee osteoarthritis treatments. MiMedx has successfully supplied over two million allografts using its proprietary PURION® process.
- Focus on expanding the late-stage pipeline for knee osteoarthritis.
- Existing supply of over two million allografts indicates strong operational capability.
- None.
MARIETTA, Ga., Feb. 15, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the fourth quarter and full year ended December 31, 2022 after the market close on Tuesday, February 28, 2023. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 5:00 p.m. Eastern Time on the same day.
The conference call can be accessed using the following information:
Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13735959
A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.
About MIMEDX
MIMEDX is a pioneer and leader in placental biologics, developing and distributing placental tissue allografts to help address unmet clinical needs in multiple sectors of healthcare, including the Advanced Wound Care market as well as in surgical recovery settings. MIMEDX is also focused on advancing a promising late-stage pipeline opportunity targeted at decreasing pain and improving function for patients with knee osteoarthritis. Our products are derived from human placental tissues and processed using our proprietary methods, including the Company’s own PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com
FAQ
What are MiMedx's fourth quarter results expected on February 28, 2023?
What will be discussed in MiMedx's conference call?
How can I access MiMedx's earnings call on February 28, 2023?
What is MiMedx's stock symbol?
